furosemide has been researched along with Birth Weight in 12 studies
Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.
furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.
Birth Weight: The mass or quantity of heaviness of an individual at BIRTH. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "When administered parenterally, furosemide, a loop diuretic, results in improved lung compliance and decreased airway resistance in infants with bronchopulmonary dysplasia (BPD)." | 9.08 | Pulmonary effect of inhaled furosemide in ventilated infants with severe bronchopulmonary dysplasia. ( Durand, M; Garg, M; Kugelman, A, 1997) |
| "To evaluate the association between furosemide exposure and risk of bronchopulmonary dysplasia (BPD)." | 7.91 | Furosemide Exposure and Prevention of Bronchopulmonary Dysplasia in Premature Infants. ( Benjamin, DK; Clark, RH; Gayam, S; Gorham, D; Greenberg, RG; Laughon, M; Savage, D; Sholomon, A; Smith, PB; Tong, A, 2019) |
| "To assess urinary aldosterone excretion (UAE) and electrolytic balance in very low-birth weight (VLBW) infants who received chronic therapy with furosemide and to compare them with those of infants who did not receive diuretic therapy." | 7.77 | Urinary aldosterone excretion and electrolytic balance in response to chronic diuretic therapy in very low-birth weight infants. ( Costa, S; Cota, F; Gallini, F; Latella, C; Maggio, L; Romagnoli, C, 2011) |
| "When administered parenterally, furosemide, a loop diuretic, results in improved lung compliance and decreased airway resistance in infants with bronchopulmonary dysplasia (BPD)." | 5.08 | Pulmonary effect of inhaled furosemide in ventilated infants with severe bronchopulmonary dysplasia. ( Durand, M; Garg, M; Kugelman, A, 1997) |
| "To evaluate the association between furosemide exposure and risk of bronchopulmonary dysplasia (BPD)." | 3.91 | Furosemide Exposure and Prevention of Bronchopulmonary Dysplasia in Premature Infants. ( Benjamin, DK; Clark, RH; Gayam, S; Gorham, D; Greenberg, RG; Laughon, M; Savage, D; Sholomon, A; Smith, PB; Tong, A, 2019) |
| "To assess urinary aldosterone excretion (UAE) and electrolytic balance in very low-birth weight (VLBW) infants who received chronic therapy with furosemide and to compare them with those of infants who did not receive diuretic therapy." | 3.77 | Urinary aldosterone excretion and electrolytic balance in response to chronic diuretic therapy in very low-birth weight infants. ( Costa, S; Cota, F; Gallini, F; Latella, C; Maggio, L; Romagnoli, C, 2011) |
| " Until now, it has been demonstrated that the RAAS of healthy neonates responds to acute furosemide challenge while no data concerning the responsiveness of RAAS in extremely low birth weight (ELBW) infants are available." | 3.75 | Urinary aldosterone excretion and renal function in extremely-low-birth-weight infants following acute furosemide therapy. ( Costa, S; De Carolis, MP; Gallini, F; Latella, C; Maggio, L; Romagnoli, C; Zecca, C, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (41.67) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Greenberg, RG | 1 |
| Gayam, S | 1 |
| Savage, D | 1 |
| Tong, A | 1 |
| Gorham, D | 1 |
| Sholomon, A | 1 |
| Clark, RH | 1 |
| Benjamin, DK | 1 |
| Laughon, M | 1 |
| Smith, PB | 1 |
| Jensen, EA | 1 |
| White, AM | 1 |
| Liu, P | 1 |
| Yee, K | 1 |
| Waber, B | 1 |
| Monk, HM | 1 |
| Zhang, H | 1 |
| Costa, S | 2 |
| Gallini, F | 2 |
| De Carolis, MP | 1 |
| Latella, C | 2 |
| Maggio, L | 2 |
| Zecca, C | 1 |
| Romagnoli, C | 2 |
| Gimpel, C | 1 |
| Krause, A | 1 |
| Franck, P | 1 |
| Krueger, M | 1 |
| von Schnakenburg, C | 1 |
| Cota, F | 1 |
| Kugelman, A | 1 |
| Durand, M | 1 |
| Garg, M | 1 |
| Lakhani, M | 1 |
| Usmani, SS | 1 |
| Wapnir, RA | 1 |
| Harper, RG | 1 |
| Aranda, JV | 1 |
| Cohen, S | 1 |
| Neims, AH | 1 |
| Ezzedeen, F | 1 |
| Adelman, RD | 1 |
| Ahlfors, CE | 1 |
| Atkinson, SA | 1 |
| Shah, JK | 1 |
| McGee, C | 1 |
| Steele, BT | 1 |
| MacGillivray, I | 1 |
| Van der Horst, RL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Retrospective Chart Review Evaluating the Impact of Steroid, Diuretic, and Fluid Use Practice Trends in Extreme Premature Infants at Risk for Bronchopulmonary Dysplasia (BPD) at a Single Center Neonatal Intensive Care Unit[NCT04971694] | 175 participants (Anticipated) | Observational | 2021-09-08 | Recruiting | |||
| Calciuric Effect and Cyclic Parenteral Nutrition in Preterm Infants[NCT00711763] | 1 participants (Actual) | Observational | 2008-07-31 | Terminated (stopped due to failure to recruit more patients and lack of supporting personnel.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for furosemide and Birth Weight
| Article | Year |
|---|---|
Pulmonary effect of inhaled furosemide in ventilated infants with severe bronchopulmonary dysplasia.
Topics: Administration, Inhalation; Birth Weight; Blood Gas Analysis; Bronchopulmonary Dysplasia; Cross-Over | 1997 |
11 other studies available for furosemide and Birth Weight
| Article | Year |
|---|---|
Furosemide Exposure and Prevention of Bronchopulmonary Dysplasia in Premature Infants.
Topics: Birth Weight; Bronchopulmonary Dysplasia; Drug Administration Schedule; Female; Furosemide; Gestatio | 2019 |
Determinants of Severe Metabolic Bone Disease in Very Low-Birth-Weight Infants with Severe Bronchopulmonary Dysplasia Admitted to a Tertiary Referral Center.
Topics: Birth Weight; Bone Diseases, Metabolic; Bronchopulmonary Dysplasia; Comorbidity; Female; Furosemide; | 2016 |
Urinary aldosterone excretion and renal function in extremely-low-birth-weight infants following acute furosemide therapy.
Topics: Aldosterone; Birth Weight; Diuresis; Diuretics; Female; Furosemide; Gestational Age; Humans; Infant, | 2009 |
Exposure to furosemide as the strongest risk factor for nephrocalcinosis in preterm infants.
Topics: Birth Weight; Calcium; Creatine; Diuretics; Female; Furosemide; Gestational Age; Humans; Infant, New | 2010 |
Urinary aldosterone excretion and electrolytic balance in response to chronic diuretic therapy in very low-birth weight infants.
Topics: Aldosterone; Birth Weight; Chlorides; Diuretics; Furosemide; Gestational Age; Humans; Infant, Newbor | 2011 |
In vitro effect of furosemide on the chemiluminescence of polymorphonuclear neutrophils in preterm infants.
Topics: Adult; Birth Weight; Cell Movement; Chemotaxis, Leukocyte; Cohort Studies; Diuretics; Dose-Response | 1997 |
Drug utilization in a newborn intensive care unit.
Topics: Ampicillin; Bicarbonates; Birth Weight; Canada; Chloramphenicol; Drug Therapy, Combination; Drug Uti | 1976 |
Renal calcification in preterm infants: pathophysiology and long-term sequelae.
Topics: Birth Weight; Calcium; Chronic Disease; Follow-Up Studies; Furosemide; Humans; Infant, Newborn; Infa | 1988 |
Mineral excretion in premature infants receiving various diuretic therapies.
Topics: Birth Weight; Bone Diseases, Metabolic; Diuretics; Drug Therapy, Combination; Female; Furosemide; Hu | 1988 |
Treatment of severe toxaemia of pregnancy.
Topics: Amobarbital; Birth Weight; Cevanes; Chlormethiazole; Female; Furosemide; Gestational Age; Heparin; H | 1972 |
Congenital atrial flutter and cardiac failure presenting as hydrops foetalis at birth.
Topics: Atrial Flutter; Birth Weight; Body Weight; Digoxin; Edema; Electrocardiography; Female; Fetal Diseas | 1970 |